Welcome to our dedicated page for Kyverna Therapeutics SEC filings (Ticker: KYTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Kyverna Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Kyverna Therapeutics's regulatory disclosures and financial reporting.
Kyverna Therapeutics reported positive topline data from KYSA-8, its registrational Phase 2 trial of mivocabtagene autoleucel (miv-cel, formerly KYV-101), a fully human, autologous CD19 CAR T-cell therapy with CD28 co-stimulation, in stiff person syndrome.
The company also stated it will host a conference call at 8:00 a.m. Eastern Time on December 15, 2025 to review the results, and made a detailed press release available describing the KYSA-8 data and its implications for the miv-cel program.
Kyverna Therapeutics (KYTX) filed its Q3 2025 10‑Q. The company reported a net loss of $36.8M for the quarter and $123.5M for the nine months ended September 30, driven by research and development of $30.5M in Q3 and $103.7M year‑to‑date, and general and administrative expenses of $8.3M in Q3 and $26.8M year‑to‑date. Interest income contributed $2.0M in Q3.
Liquidity remained solid with cash, cash equivalents and marketable securities of $171.1M as of September 30, 2025. Operating cash outflow was $120.2M year‑to‑date. Subsequent to quarter‑end, the company entered a term loan facility of up to $150.0M and drew $25.0M on November 3, 2025; the facility bears interest at 1‑Month CME Term SOFR (floor 3.75%) plus 5.00% and matures on October 1, 2030, with interest‑only payments through at least November 1, 2028.
Management estimates that, with the initial $25.0M loan funding, existing balances will fund operations for at least the next 12 months from issuance. As additional flexibility, a shelf registration allows offerings up to $250.0M, including an at‑the‑market program with $50.0M available as of quarter‑end. Shares outstanding were 43,796,170 as of October 31, 2025.
Kyverna Therapeutics, Inc. (KYTX) furnished an 8-K announcing it issued a press release with a business update and financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company states the information under Item 2.02 and Exhibit 99.1 is furnished, not filed, under the Exchange Act and will not be incorporated by reference into Securities Act or Exchange Act filings unless specifically referenced. The report was signed by Chief Financial Officer Marc Grasso, M.D.
Kyverna Therapeutics (KYTX) entered a non-dilutive term loan facility of up to $150.0 million with Oxford Finance, structured in multiple tranches. The facility includes an initial $40.0 million tranche and two additional tranches totaling $60.0 million, with a discretionary fourth tranche of $50.0 million. The company expects to draw $25.0 million from the first tranche on November 3, 2025.
The loan matures on October 1, 2030 and bears a floating rate equal to the greater of the 1‑Month CME Term SOFR or 3.75%, plus 5.00%. Kyverna will make interest-only payments until November 1, 2028 or, at its option upon meeting certain milestones, until November 1, 2029, after which principal and interest are due monthly. The agreement is secured by substantially all assets, including intellectual property, and includes customary events of default.
The company also announced it now expects to report topline registrational data for its Phase 2 KYV‑101 trial in stiff person syndrome in early 2026.
Kyverna Therapeutics (KYTX) announced positive interim data from the Phase 2 portion of its KYSA-6 Phase 2/3 trial of KYV-101 in generalized myasthenia gravis. The company will host a conference call at 8:00 a.m. Eastern Time on October 29, 2025 to review the results.
Slides for the call are furnished as Exhibit 99.1. The information was furnished under Item 7.01 and is not deemed “filed” under the Exchange Act.
Kyverna Therapeutics (KYTX) announced positive interim data from the Phase 2 portion of its KYSA-6 Phase 2/3 trial evaluating KYV-101 in generalized myasthenia gravis. The company scheduled a conference call at 8:00 a.m. Eastern Time on October 29, 2025 to review the results. The announcement was provided under Regulation FD to ensure broad, simultaneous disclosure.
The details were furnished as Exhibit 99.1 and, consistent with Regulation FD practice, are not deemed “filed” for purposes of Section 18 of the Exchange Act. This signals a clinical program update rather than a change to financial statements or guidance. The filing lists the press release and the Inline XBRL cover page as exhibits.
Kyverna Therapeutics, Inc. reported a change in its board leadership. Steve Liapis, Ph.D. notified the company on September 19, 2025 that he will resign as a member of the board of directors and all related committees, effective September 30, 2025. The company states that his resignation is not due to any disagreement with its operations, policies, or practices.
After his departure, the size of the board will be reduced from eight to seven directors. The board has appointed current director Christi Shaw to the Audit Committee to fill the vacancy created by Dr. Liapis’ resignation. The board also expressed appreciation for Dr. Liapis’ years of service and contributions.
Kyverna Therapeutics is a clinical-stage biopharma developing CAR T cell therapies for autoimmune diseases. For the quarter ended June 30, 2025, the company reported a net loss of $42.1 million and a six-month net loss of $86.7 million, with net loss per share of $0.97 for the quarter. Accumulated deficit stood at $350.2 million. As of June 30, 2025, Kyverna held $53.4 million in cash and $158.2 million in available-for-sale marketable securities, totaling $211.7 million of liquidity; management estimates this funding is sufficient for at least the next 12 months and into 2027 under the current plan.
Operationally, Kyverna completed enrollment in its registrational Phase 2 KYSA-8 study for stiff person syndrome in Q2 2025 and expects data in the first half of 2026. The KYSA-6 trial in myasthenia gravis has completed enrollment, interim data are planned for Q4 2025, and the trial is being expanded to include a Phase 3 portion expected to begin enrollment by year-end 2025. The company also noted FDA alignment on CMC readiness and plans to support a BLA filing for SPS in the first half of 2026. The company faces securities class and derivative litigation; no loss accruals were recorded as of June 30, 2025.
Kyverna Therapeutics, Inc. furnished a press release providing a business update and reporting financial results for the quarter ended June 30, 2025. The press release is attached to the report as Exhibit 99.1.
The company notes this information is furnished, not filed, and therefore is not subject to Section 18 liability and is not automatically incorporated by reference into registration statements. Kyverna's common stock trades on Nasdaq under the symbol KYTX, and the registrant is identified as an emerging growth company.
Kyverna Therapeutics (ticker KYTX) filed a Form 4 disclosing that its Chief Financial Officer, Marc Grasso, received an equity award on 30 June 2025. The transaction involves a single grant of 450,000 stock options with an exercise price of $3.07 and an expiration date of 30 June 2035.
The vesting schedule follows a standard four-year pattern: 25 % (112,500 options) vests on 30 June 2026, after which 1⁄48 of the total options (9,375 shares) vest monthly for the next 36 months, contingent on Grasso’s continued employment. The filing shows direct ownership (D) of the derivative security, and no other changes to common-stock holdings were reported.
This award aligns the CFO’s incentives with long-term shareholder value creation and signals a retention commitment by the company. If fully exercised, the award would add up to 450,000 new common shares to the float, a modest potential dilution given Kyverna’s recent post-IPO share count of roughly 55-60 million (based on prior filings). No cash transactions were reported, and the filing contains no earnings or operational updates.